{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:12:23Z","timestamp":1791447143533,"version":"4.3.3"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T00:00:00Z","timestamp":1559779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,6,6]],"date-time":"2019-06-06T00:00:00Z","timestamp":1559779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The SUSTAIN 6 trial demonstrated that once-weekly semaglutide (0.5 and 1.0\u00a0mg) significantly reduced major adverse cardiovascular (CV) events (MACE) vs placebo in subjects with type 2 diabetes (T2D) and high CV risk. The effects of gender, age and baseline CV risk on outcomes are important considerations for further study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Subjects were grouped according to gender, age (50\u201365\u00a0years and &gt;\u200965\u00a0years), and CV risk profile at baseline (prior myocardial infarction [MI] or stroke vs no prior MI or stroke, and established CV disease [CVD] vs CV risk factors alone, including subjects with chronic kidney disease). Time to MACE and its individual components (CV death, nonfatal MI, nonfatal stroke), hospitalization for unstable angina or heart failure, and revascularization (coronary and peripheral) were analyzed for all subgroups. Additional analyses were performed for gender and age to investigate change from baseline in HbA\n                      <jats:sub>1c<\/jats:sub>\n                      and body weight, as well as tolerability.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 3297 subjects were included. The majority of subjects (60.7%) were male; 43% were &gt;\u200965\u00a0years of age; 41.5% had a history of MI or stroke; and 76.8% had established CVD. Compared with placebo, semaglutide reduced the risk of the first occurrence of MACE and each MACE component consistently across all subgroups (gender, age, and baseline CV risk profile). Revascularizations, HbA\n                      <jats:sub>1c<\/jats:sub>\n                      and body weight were also reduced consistently across all subgroups compared with placebo. Gastrointestinal adverse events in all treatment groups were more common among women than men, but rates of premature treatment discontinuation were similar for both genders.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this post hoc analysis of SUSTAIN 6, once-weekly semaglutide vs placebo reduced the risk of MACE in all subjects included in the trial, regardless of gender, age, or baseline CV risk profile.<\/jats:p>\n                    <jats:p>\n                      <jats:italic>Trial registry<\/jats:italic>\n                      Clinicaltrials.gov, Identifying number: NCT01720446, Date of registration: October 29, 2012\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12933-019-0871-8","type":"journal-article","created":{"date-parts":[[2019,6,5]],"date-time":"2019-06-05T19:03:12Z","timestamp":1559761392000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":112,"title":["Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial"],"prefix":"10.1186","volume":"18","clinical-trial-number":[{"clinical-trial-number":"nct01720446","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Lawrence A.","family":"Leiter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen C.","family":"Bain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Hramiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esteban","family":"J\u00f3dar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sten","family":"Madsbad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theis","family":"Gondolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Holst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ildiko","family":"Lingvay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,6]]},"reference":[{"issue":"Suppl 1","key":"871_CR1","first-page":"S1","volume":"41","author":"American Diabetes Association","year":"2018","unstructured":"American Diabetes Association. Standards of medical care in diabetes 2018. Diabetes Care. 2018;41(Suppl 1):S1\u2013135.","journal-title":"Diabetes Care"},{"issue":"Suppl 1","key":"871_CR2","doi-asserted-by":"publisher","first-page":"S103","DOI":"10.2337\/dc19-S010","volume":"42","author":"American Diabetes Association","year":"2019","unstructured":"American Diabetes Association. Cardiovascular disease and risk management: standards of medical care in diabetes 2019. Diabetes Care. 2019;42(Suppl 1):S103\u201323.","journal-title":"Diabetes Care"},{"key":"871_CR3","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1016\/S0140-6736(10)60484-9","volume":"375","author":"N Sarwar","year":"2010","unstructured":"Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215\u201322.","journal-title":"Lancet"},{"issue":"41","key":"871_CR4","doi-asserted-by":"publisher","first-page":"2669","DOI":"10.2337\/dci18-0033","volume":"2018","author":"MJ Davies","year":"2018","unstructured":"Davies MJ, D\u2019Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;2018(41):2669\u2013701.","journal-title":"Diabetes Care"},{"key":"871_CR5","doi-asserted-by":"publisher","first-page":"7370","DOI":"10.1021\/acs.jmedchem.5b00726","volume":"58","author":"J Lau","year":"2015","unstructured":"Lau J, Bloch P, Sch\u00e4ffer L, Pettersson I, Spetzler J, Kofoed J, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58:7370\u201380.","journal-title":"J Med Chem"},{"key":"871_CR6","unstructured":"Ozempic marketing authorisation 2018. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ozempic. Accessed 7 May 2019."},{"key":"871_CR7","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","volume":"5","author":"C Sorli","year":"2017","unstructured":"Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsb\u00f8l JD, Hansen T, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5:251\u201360.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"871_CR8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","volume":"5","author":"B Ahr\u00e9n","year":"2017","unstructured":"Ahr\u00e9n B, Masmiquel L, Kumar H, Sargin M, Karsb\u00f8l JD, Jacobsen SH, et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial. Lancet Diabetes Endocrinol. 2017;5:341\u201354.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"871_CR9","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2337\/dc17-0417","volume":"41","author":"AJ Ahmann","year":"2018","unstructured":"Ahmann AJ, Capehorn M, Charpentier G, Dotta F, Henkel E, Lingvay I, et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018;41:258\u201366.","journal-title":"Diabetes Care"},{"key":"871_CR10","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","volume":"5","author":"VR Aroda","year":"2017","unstructured":"Aroda VR, Bain SC, Cariou B, Pileti\u0107 M, Rose L, Axelsen M, et al. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes Endocrinol. 2017;5:355\u201366.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"871_CR11","doi-asserted-by":"publisher","first-page":"2291","DOI":"10.1210\/jc.2018-00070","volume":"103","author":"HW Rodbard","year":"2018","unstructured":"Rodbard HW, Lingvay I, Reed J, de la Rosa R, Rose L, Sugimoto D, et al. Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial. J Clin Endocrinol Metab. 2018;103:2291\u2013301.","journal-title":"J Clin Endocrinol Metab"},{"key":"871_CR12","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, Eliaschewitz FG, J\u00f3dar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834\u201344.","journal-title":"N Engl J Med"},{"key":"871_CR13","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S2213-8587(18)30024-X","volume":"6","author":"RE Pratley","year":"2018","unstructured":"Pratley RE, Aroda VR, Lingvay I, L\u00fcdemann J, Andreassen C, Navarria A, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol. 2018;6:275\u201386.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"871_CR14","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/S2213-8587(19)30066-X","volume":"7","author":"B Zinman","year":"2019","unstructured":"Zinman B, Bhosekar V, Busch R, Holst I, Ludvik B, Thielke D, et al. Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo controlled trial. Lancet Diab Endocrinol. 2019;7:356\u201367.","journal-title":"Lancet Diab Endocrinol"},{"key":"871_CR15","unstructured":"International Conference on Harmonisation-World Health Organization Guideline for Good Clinical Practice. ICH harmonised tripartite guideline good clinical practice 2016. https:\/\/www.ich.org\/products\/guidelines\/efficacy\/efficacy-single\/article\/integrated-addendum-good-clinical-practice.html. Accessed 22 Mar 2019."},{"key":"871_CR16","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191\u20134.","journal-title":"JAMA"},{"key":"871_CR17","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.2337\/dc12-2480","volume":"36","author":"ER Seaquist","year":"2013","unstructured":"Seaquist ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al. Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care. 2013;36:1384\u201395.","journal-title":"Diabetes Care"},{"key":"871_CR18","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12933-018-0760-6","volume":"17","author":"N Shehadeh","year":"2018","unstructured":"Shehadeh N, Raz I, Nakhleh A. Cardiovascular benefit in the limelight: shifting type 2 diabetes treatment paradigm towards early combination therapy in patients with overt cardiovascular disease. Cardiovasc Diabetol. 2018;17:117.","journal-title":"Cardiovasc Diabetol"},{"key":"871_CR19","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, K\u00f8ber LV, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373:2247\u201357.","journal-title":"N Engl J Med"},{"key":"871_CR20","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311\u201322.","journal-title":"N Engl J Med"},{"key":"871_CR21","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377:1228\u201339.","journal-title":"N Engl J Med"},{"key":"871_CR22","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez AF, Green JB, Janmohamed S, D\u2019Agostino RB Sr, Granger CB, Jones NP, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392:1519\u201329.","journal-title":"Lancet"},{"key":"871_CR23","unstructured":"Eli Lilly Press release, 2018. Trulicity\u00ae (dulaglutide) demonstrates superiority in reduction of cardiovascular events for broad range of people with type 2 diabetes. https:\/\/investor.lilly.com\/node\/39796\/pdf. Accessed May 2018."},{"key":"871_CR24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12933-017-0512-z","volume":"16","author":"Z Zhang","year":"2017","unstructured":"Zhang Z, Chen X, Lu P, Zhang J, Xu Y, He W, et al. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes. Cardiovasc Diabetol. 2017;16:31.","journal-title":"Cardiovasc Diabetol"},{"key":"871_CR25","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s11886-018-1051-2","volume":"20","author":"Y Li","year":"2018","unstructured":"Li Y, Rosenblit PD. Glucagon-like peptide-1 receptor agonists and cardiovascular risk reduction in type 2 diabetes mellitus: is it a class effect? Curr Cardiol Rep. 2018;20:113.","journal-title":"Curr Cardiol Rep"},{"key":"871_CR26","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s13300-018-0424-2","volume":"9","author":"M Witkowski","year":"2018","unstructured":"Witkowski M, Wilkinson L, Webb N, Weids A, Glah D, Vrazic H. A systematic literature review and network meta-analysis comparing once-weekly semaglutide with other GLP-1 receptor agonists in patients with type 2 diabetes previously receiving 1\u20132 oral anti-diabetic drugs. Diabetes Ther. 2018;9:1149\u201367.","journal-title":"Diabetes Ther"},{"key":"871_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2018.12.001","author":"V Aroda","year":"2019","unstructured":"Aroda V, Ahmann A, Cariou B, Chow F, Davies MJ, J\u00f3dar E, et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: insights from the SUSTAIN 1\u20137 trials. Diabetes Metab. 2019. https:\/\/doi.org\/10.1016\/j.diabet.2018.12.001 (Epub ahead of print).","journal-title":"Diabetes Metab"},{"key":"871_CR28","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.diabet.2018.09.002","volume":"45","author":"BM Mishriky","year":"2019","unstructured":"Mishriky BM, Cummings DM, Powell JR, Sewell KA, Tanenberg RJ. Comparing once-weekly semaglutide to incretin-based therapies in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes Metab. 2019;45:102\u20139.","journal-title":"Diabetes Metab"},{"key":"871_CR29","doi-asserted-by":"publisher","first-page":"e009304","DOI":"10.1161\/JAHA.118.009304","volume":"7","author":"RJ Mentz","year":"2018","unstructured":"Mentz RJ, Bethel MA, Merrill P, Lokhnygina Y, Buse JB, Chan JC, et al. Effect of once-weekly exenatide on clinical outcomes according to baseline risk in patients with type 2 diabetes mellitus: insights from the EXSCEL trial. J Am Heart Assoc. 2018;7:e009304.","journal-title":"J Am Heart Assoc"},{"key":"871_CR30","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1007\/s00125-014-3260-6","volume":"57","author":"SA Peters","year":"2014","unstructured":"Peters SA, Huxley RR, Woodward M. Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia. 2014;57:1542\u201351.","journal-title":"Diabetologia"},{"key":"871_CR31","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.2337\/dc08-0194","volume":"31","author":"I Gouni-Berthold","year":"2008","unstructured":"Gouni-Berthold I, Berthold HK, Mantzoros CS, B\u00f6hm M, Krone W. Sex disparities in the treatment and control of cardiovascular risk factors in type 2 diabetes. Diabetes Care. 2008;31:1389\u201391.","journal-title":"Diabetes Care"},{"key":"871_CR32","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.genm.2010.12.001","volume":"7","author":"A Kautzky-Willer","year":"2010","unstructured":"Kautzky-Willer A, Kamyar MR, Gerhat D, Handisurya A, Stemer G, Hudson S, et al. Sex-specific differences in metabolic control, cardiovascular risk, and interventions in patients with type 2 diabetes mellitus. Gend Med. 2010;7:571\u201383.","journal-title":"Gend Med"},{"key":"871_CR33","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2169\/internalmedicine.51.6094","volume":"51","author":"M Sekerija","year":"2012","unstructured":"Sekerija M, Poljicanin T, Erjavec K, Liberati-Cizmek AM, Prasek M, Metelko Z. Gender differences in the control of cardiovascular risk factors in patients with type 2 diabetes\u2014a cross-sectional study. Intern Med. 2012;51:161\u20136.","journal-title":"Intern Med"},{"key":"871_CR34","doi-asserted-by":"publisher","DOI":"10.7326\/m18-1569","author":"MP Gilbert","year":"2018","unstructured":"Gilbert MP, Bain SC, Franek E, Jodar-Gimeno E, Nauck MA, Pratley R, et al. Effect of liraglutide on cardiovascular outcomes in elderly patients: a post hoc analysis of a randomized controlled trial. Ann Intern Med. 2018. https:\/\/doi.org\/10.7326\/m18-1569.","journal-title":"Ann Intern Med"},{"key":"871_CR35","unstructured":"National Diabetes Statistics Report. 2017. https:\/\/www.cdc.gov\/diabetes\/pdfs\/data\/statistics\/national-diabetes-statistics-report.pdf. Accessed 7 May 2019."},{"key":"871_CR36","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1001\/jama.2010.1322","volume":"304","author":"DL Bhatt","year":"2010","unstructured":"Bhatt DL, Eagle KA, Ohman EM, Hirsch AT, Goto S, Mahoney EM, et al. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010;304:1350\u20137.","journal-title":"JAMA"},{"key":"871_CR37","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1161\/CIRCULATIONAHA.118.034516","volume":"138","author":"S Verma","year":"2018","unstructured":"Verma S, Poulter NR, Bhatt DL, Bain SC, Buse JB, Leiter LA, et al. Effects of liraglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus with or without history of myocardial infarction or stroke. Circulation. 2018;138:2884\u201394.","journal-title":"Circulation"},{"key":"871_CR38","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/dom.13028","volume":"20","author":"HC Gerstein","year":"2018","unstructured":"Gerstein HC, Colhoun HM, Dagenais GR, Diaz R, Lakshmanan M, Pais P, et al. Design and baseline characteristics of participants in the Researching cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) trial on the cardiovascular effects of dulaglutide. Diabetes Obes Metab. 2018;20:42\u20139.","journal-title":"Diabetes Obes Metab"},{"key":"871_CR39","unstructured":"NCT03811561. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03811561. Accessed 7 May 2019."},{"key":"871_CR40","unstructured":"NCT03819153. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03819153. Accessed 7 May 2019."},{"key":"871_CR41","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMsr077003","volume":"357","author":"R Wang","year":"2007","unstructured":"Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine\u2014reporting of subgroup analyses in clinical trials. N Engl J Med. 2007;357:2189\u201394.","journal-title":"N Engl J Med"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-019-0871-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-019-0871-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-019-0871-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T12:12:32Z","timestamp":1628597552000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-019-0871-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,6]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["871"],"URL":"https:\/\/doi.org\/10.1186\/s12933-019-0871-8","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,6]]},"assertion":[{"value":"31 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The protocol was approved by local ethics committees and institutional review boards at each participating center. All subjects provided written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"During the conduct of the study, L.A.L. received research grants to his institution from Novo Nordisk. Outside of the submitted work, he has received grants and\/or personal fees for advisory panels, speakers\u2019 bureaus, and research support from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Janssen Pharmaceuticals, Merck, Novo Nordisk, and Sanofi. He also reports research grants from GlaxoSmithKline and personal fees for advisory panels from Servier.Outside the submitted work, S.C.B. has received honoraria, teaching, and research sponsorship\/grants from Abbott, AstraZeneca, Boehringer Ingelheim, Cellnovo, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk, and Sanofi-aventis, Cardiff University, Doctors.net, Elsevier, Onmedica, Omnia-Med, Medscape, All-Wales Medicines Strategy Group, National Institute for Health and Care Excellence (NICE) UK, and Glycosmedia.Outside the submitted work, I.H. reports research grants and\/or personal fees from AstraZeneca\/Bristol-Myers Squibb, Boehringer Ingelheim, Dexcom, Eli Lilly, GlaxoSmithKline, Insulet Corp, Janssen Pharmaceuticals, Lexicon Pharmaceuticals, Medtronic, Merck & Co Inc, Population Health Research Institute, Roche Pharma, Sanofi, and Takeda.E.J. reports grants and personal fees from Novo Nordisk during the conduct of the study. He also reports grants and personal fees as a consultant and\/or speaker from Amgen, AstraZeneca, Boehringer Ingelheim, Faes Farma, Fresenius, Janssen Pharmaceuticals, Eli Lilly, Merck Sharp & Dohme, Novartis, Novo Nordisk, Pfizer, Sanofi, Shire, and UCB.Outside of the submitted work, S.M. has received honoraria and\/or lecture fees from AstraZeneca, Boehringer Ingelheim, Bristol-Meyers Squibb, Eli Lilly, Intarcia Therapeutics, Johnson & Johnson, Merck Sharp & Dohme, Novartis, Novo Nordisk, and Sanofi Aventis. He has also received a research grant from Novo Nordisk and Boehringer Ingelheim.T.G., T.H., and I.H. report that they are full-time employees of Novo Nordisk A\/S.I.L. received research grants to her institution and consulting fees from Novo Nordisk during the conduct of the study. Outside the submitted work, she has received grants and\/or personal fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, GI Dynamics, Intarcia, Mannkind, Merck, Mylan, Novartis, NovoNordisk, Pfizer, Sanofi, TARGETPharma, and Valeritas.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"73"}}